Skip NavigationSkip to Content

Mucin 17 inhibits the progression of human gastric cancer by limiting inflammatory responses through a MYH9-p53-RhoA regulatory feedback loop

  1. Author:
    Yang, Bing
    Wu, Aiwen
    Hu, Yingqi
    Tao, Cuijian
    Wang,Jiming
    Lu, Youyong
    Xing, Rui
  2. Author Address

    Laboratory of Molecular Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Fu-Cheng Road 52#, Hai-Dian District, Beijing, 100142, China., Cancer and Inflammation Program Center for Cancer Research, National Cancer Institute at Frederick, Frederick, MD, USA., Laboratory of Molecular Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital & Institute, Fu-Cheng Road 52#, Hai-Dian District, Beijing, 100142, China. xingrui@bjmu.edu.cn.,
    1. Year: 2019
    2. Date: Jul 01
    3. Epub Date: 2019 07 01
  1. Journal: Journal of experimental & clinical cancer research : CR
    1. 38
    2. 1
    3. Pages: 283
  2. Type of Article: Article
  3. Article Number: 283
  4. ISSN: 1756-9966
  1. Abstract:

    Mucins are key components of the mucosal barrier in the stomach that protects epithelia from carcinogenic effects of chronic inflammation. Analysis of The Cancer Genome Atlas database indicated that mucin-17 (MUC17) was more highly expressed in gastric cancer (GC) specimens, with favourable prognosis for patients. To explore the underlying mechanisms, we investigated the potential role of MUC17 in controlling chronic gastric inflammation. We initially quantified the expression of MUC17 and inflammatory factor, as well as the association of MUC17 with survive in GC using immunohistochemistry. To establish how the inflammatory factors affect MUC17 expression, we explored luciferase reporter, chromatin immunoprecipitation (ChIP), and electrophoretic mobility shift (EMSA) assays. The role and mechanism that MUC17 plays in inflammation-induced cell proliferation was examined in AGS cells with reduced MUC17 expression and MKN45 cells overexpressing a truncated MUC17. We found MUC17 was induced by inflammatory cytokines in GC cells via CDX1upregulation. MUC17 thus inactivated NF?B to inhibit GC cell proliferation in response to pro-inflammatory cytokines. We also revealed that the function of MUC17 was dependent on its conserved epidermal growth factor domain and on downstream sequences to enable its interaction with myosin-9, resulting in a sustained regulatory feedback loop between myosin-9, p53, and RhoA, and then activation of p38 to negatively regulate the NF?B pathway in GC cells. This mechanism was also confirmed in vivo. Our study demonstrates MUC17 as a GC suppressor protein which has the therapeutic potential for human GC.

    See More

External Sources

  1. DOI: 10.1186/s13046-019-1279-8
  2. PMID: 31262330
  3. WOS: 000473508900002
  4. PII : 10.1186/s13046-019-1279-8

Library Notes

  1. Fiscal Year: FY2018-2019
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel